Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Insulin secretion and repaglinide].

D Owens

    Diabetes & Metabolism
    |April 4, 2000
    PubMed
    Summary
    This summary is machine-generated.

    Type 2 diabetes involves progressive beta-cell dysfunction and insulin resistance. Newer insulin enhancers like repaglinide offer improved glucose control with reduced hypoglycemia risk.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Twenty-seven years of primary salivary gland carcinoma in Wales: an analysis of histological subtype and associated risk factors.

    The Journal of laryngology and otology·2022
    Same author

    Enhancement of a low-fidelity surgical simulator. Is it possible?

    The Journal of laryngology and otology·2021
    Same author

    Application of medium-term metrics for assessing glucose homoeostasis: Usefulness, strengths and weaknesses.

    Diabetes & metabolism·2020
    Same author

    Number Needed-to-Treat (NNT): Is it a necessary marker of therapeutic efficiency?

    Diabetes & metabolism·2020
    Same author

    Calibration free continuous glucose monitoring (CGM) devices: Weighing up the benefits and limitations.

    Diabetes & metabolism·2019
    Same author

    Can smartphone vibration provide a valid alternative to tuning forks for use on the ENT ward round?

    The Journal of laryngology and otology·2019
    Same journal

    Glucagon-like peptide-1 receptor agonists and risk of pancreaticobiliary cancers in patients with type 2 diabetes: a nationwide cohort study.

    Diabetes & metabolism·2026
    Same journal

    Decreased risk of new-onset osteoporosis in patients with Type 2 diabetes on SGLT-2 inhibitors.

    Diabetes & metabolism·2026
    Same journal

    Two faces of autoimmune hyperinsulinemia: contrasting type B insulin resistance syndrome and exogenous insulin antibody syndrome.

    Diabetes & metabolism·2026
    Same journal

    CGM-based metrics and mortality in older adults living with type 2 diabetes on insulin therapy: a secondary analysis of the HYPOAGE study.

    Diabetes & metabolism·2026
    Same journal

    Persistent burden and management gaps of hypoglycemia in pediatric type 1 diabetes: insights from the Epi-GLUREDIA Study.

    Diabetes & metabolism·2026
    Same journal

    Blood oxygen saturation and its associations with autonomic and peripheral neuropathy in diabetes.

    Diabetes & metabolism·2026
    See all related articles

    Area of Science:

    • Endocrinology
    • Metabolic Diseases
    • Pharmacology

    Background:

    • Type 2 diabetes is characterized by progressive pancreatic beta-cell dysfunction, leading to abnormal insulin secretion and insulin resistance, primarily in muscles.
    • These abnormalities are present early in glucose intolerance, but their underlying causes are not fully understood.
    • The high prevalence, increasing incidence, and significant healthcare costs associated with type 2 diabetes highlight its status as a major public health concern.

    Purpose of the Study:

    • To review the natural history of type 2 diabetes.
    • To discuss current therapeutic approaches and their limitations.
    • To explore the potential of newer insulin secretagogues in managing type 2 diabetes.

    Main Methods:

    • Literature review of type 2 diabetes pathophysiology and treatment.

    Related Experiment Videos

  • Analysis of existing drug classes (sulfonylureas, metformin, acarbose) and their outcomes (e.g., UKPDS trial).
  • Discussion of novel insulin secretagogues, focusing on repaglinide's mechanism and benefits.

    • Main Results:

    • Traditional therapies like sulfonylureas, metformin, and acarbose have shown efficacy but possess limitations in long-term glycemic control, hypoglycemia risk, and macrovascular complication prevention.
    • Newer insulin secretagogues, exemplified by repaglinide, demonstrate potential for improved outcomes.
    • Repaglinide offers reduced total insulin levels, enhanced nutrient-stimulated insulin secretion, and a minimized risk of hypoglycemia.

    Conclusions:

    • Effective management of type 2 diabetes requires earlier diagnosis and intensive treatment strategies.
    • While established therapies are beneficial, they have limitations that impact long-term patient outcomes.
    • Emerging insulin secretagogues represent a promising advancement in the treatment of type 2 diabetes, offering potential for better glycemic control and safety profiles.